このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

変形性関節症または軟骨損傷による膝の痛みに対するCartiPROの長期研究

2026年9月30日 更新者:DALIM TISSEN Co., Ltd.

骨関節炎および/または多様な軟骨欠損を有する患者の膝痛緩和に対するCartiPRO注射の長期有効性および安全性:多施設共同、単盲検、無作為化、非劣性、スポンサー主導試験

This clinical trial aims to evaluate and compare the efficacy and safety of CartiPRO, an approved intra-articular atelocollagen injection, versus Synovian injection for the relief of knee pain in patients with knee osteoarthritis. The investigational device is administered intra-articularly, with a second injection given 24 weeks after the first dose. Primary and secondary endpoints include changes in pain scores (VAS), functional assessments (WOMAC, SF-36), and safety evaluations over a 36-week period.

調査の概要

詳細な説明

Knee osteoarthritis (OA) is the most common joint disorder, primarily caused by the destruction of articular cartilage. Symptoms typically include joint pain, stiffness, and muscle contraction. According to the World Health Organization, in 2013, an estimated 10-15% of adults over the age of 60 were affected by OA, significantly impacting their quality of life.

Collagen degradation is a key feature of cartilage damage in OA. Collagen-based injectable materials, such as atelocollagen, are being explored as potential therapeutic options to restore collagen and improve clinical outcomes. Unlike other injectable substances like hyaluronic acid or corticosteroids, collagen's stable triple helix structure and long half-life make it more resistant to enzymatic degradation, offering a potentially longer-lasting effect.

Despite this, long-term and repeated use data for atelocollagen injections in knee OA are limited both domestically and internationally. This study aims to provide robust clinical evidence on the efficacy and safety of repeated intra-articular atelocollagen injections for knee pain relief in patients with knee OA.

This is a randomized, single-blind, active-controlled study comparing CartiPRO with Synovian. Subjects with knee OA and symptomatic knee pain will receive the investigational device intra-articularly. A second dose will be administered at 24 weeks. The primary outcome is the change in 100-mm weight-bearing pain (WBP) VAS score at 12 weeks compared to baseline.

Secondary outcomes include VAS changes in WBP, resting pain (RP), motion pain (MP), and night pain (NP) at multiple time points, as well as changes in WOMAC and SF-36 scores. Long-term efficacy will be assessed after re-injection. Safety assessments include adverse events, local reactions, physical examination, vital signs, and laboratory tests.

Study Visits:

Visit 1: Screening Visit 2: First injection (baseline) Visit 3: 2 weeks after injection Visit 4: 4 weeks after injection Visit 5: 12 weeks after injection Visit 6: 24 weeks after injection (second dose) Visit 7: 36 weeks after first injection

研究の種類

介入

入学 (推定)

194

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Bundang-gu
      • Seongnam-si、Bundang-gu、韓国、13620
        • Seoul National University Bundang Hospital
      • Seoul、Bundang-gu、韓国、13496
        • CHA Bundang Medical Center
    • Eunpyeong-gu
      • Seoul、Eunpyeong-gu、韓国、03312
        • The Catholic University of Korea Eunpyeong St. Mary's Hospital
    • Namdong-gu
      • Seoul、Namdong-gu、韓国、21565
        • Gachon University Gil Hospital
    • Seochogu
      • Seoul、Seochogu、韓国、06591
        • The Catholic University of Korea Seoul St. Mary's Hospital

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

19年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria

  • Age 19 years and older

  • Diagnosed with unilateral or bilateral knee osteoarthritis according to American College of Rheumatology (ACR) criteria, with at least 3 of the following 6 features:

    • Age ≥50 years
    • Morning stiffness <30 minutes
    • Crepitus on active motion
    • Bony tenderness
    • Bony enlargement
    • No palpable warmth
  • Radiographic evidence of Kellgren-Lawrence grade I, II, or III osteoarthritis within 6 months prior to screening or at screening visit

  • Weight-bearing pain Visual Analogue Scale (VAS) score ≥40 mm in at least one knee joint at screening

  • Able to walk without assistive devices (walkers or canes), OR if using a walking aid routinely for past 6 months, able to continue using the same device throughout the study

  • Able to understand and complete efficacy assessment questionnaires

  • Willing and able to provide written informed consent

Exclusion Criteria

  • Body Mass Index (BMI) ≥32 kg/m²
  • Chronic inflammatory joint disease (e.g., rheumatoid arthritis)
  • Inflammatory joint disease (e.g., septic arthritis)
  • Secondary knee osteoarthritis due to ochronosis, hemochromatosis, or systemic disease
  • Painful musculoskeletal conditions (e.g., Sudeck's atrophy, Paget's disease, herniated intervertebral disc)
  • Polyarticular disease with severe osteoarthritis in other joints (e.g., hip) that may affect knee pain evaluation
  • Radiographic evidence of definite loss of patellofemoral joint space
  • Moderate to severe joint effusion confirmed by positive patellar tap test or equivalent
  • History of myocardial infarction, congestive heart failure, other serious cardiac disease, or uncontrolled hypertension (≥140/90 mmHg despite treatment with ≥3 antihypertensive agents)
  • History of autoimmune disease
  • Active infection requiring parenteral antibiotics
  • History of psychiatric disorder or epilepsy
  • Cancer diagnosis within 5 years prior to screening
  • Uncontrolled type 1 or type 2 diabetes mellitus (HbA1c >7%)
  • Surgical procedures (including arthroscopy) on target knee within 1 year (surgery on contralateral knee or hip may be exclusionary if it could affect target knee assessment)
  • Intra-articular corticosteroid injection into target knee within 12 weeks
  • Systemic corticosteroid use within 4 weeks (topical and inhaled corticosteroids permitted)
  • Surgery or radiation therapy to knee joint within 12 weeks, or not fully recovered from side effects
  • Immunosuppressive therapy (e.g., Cyclosporine A, Azathioprine) within 6 weeks
  • Intra-articular injections (e.g., hyaluronic acid) into knee joint within 6 months
  • Prohibited concomitant medications within 2 weeks (unless washout period is adequate)
  • Anticoagulants (e.g., warfarin, NOACs), antiplatelet agents (e.g., aspirin >100 mg/day, clopidogrel; low-dose aspirin ≤100 mg/day permitted), thrombolytic agents (e.g., urokinase, alteplase), or Vitamin E >1000 IU/day within 2 weeks (unless adequate washout)
  • Habitual use (≥3 months) of psychoactive drugs or narcotic analgesics that may affect pain perception
  • History of cell therapy or gene therapy to target joint
  • Planned cell therapy or gene therapy to target joint
  • Abnormal laboratory values at screening:
  • ALT, AST, BUN, or serum creatinine >2× upper limit of normal
  • Engaged in high-intensity aerobic or heavy anaerobic exercise that may affect the knee joint
  • Dermatological disease at injection site or site deemed unsuitable for injection
  • Ligament instability of Grade II or higher in target knee (Grade 0: none; Grade I: 0-5 mm; Grade II: 5-10 mm; Grade III: >10 mm)
  • Known hypersensitivity to investigational product or its components
  • Pregnant or breastfeeding women
  • Women or men of childbearing potential unwilling to use acceptable contraception during study (acceptable methods: intrauterine device, tubal ligation, sterilization surgery, condom or diaphragm with spermicide, natural family planning)
  • Participation in another clinical trial within 4 weeks
  • Cognitive impairment or dementia preventing informed consent
  • Any other condition that makes the subject unsuitable for study participation per investigator judgment

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:支持療法
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:ダブル

武器と介入

参加者グループ / アーム
介入・治療
実験的:Study Group

Group applied with CartiPRO

Clinical subjects are enrolled after the investigator confirms eligibility, and subjects in the study group receive treatment Dalim Tissen's CartiPRO.

Intra-articular medical device injection at baseline and Week 12; final assessment at Week 36.

アクティブコンパレータ:Control group

Group applied with Synovian®

Clinical subjects are enrolled after the investigator confirms eligibility, and subjects in the study group receive treatment Synovian®. Intra-articular medical device injection at baseline and Week 12; final assessment at Week 36.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Change from baseline in 100-mm Weight-Bearing Pain (WBP) Visual Analogue Scale (VAS) score (0-100 mm)
時間枠:at week 12 after the first administration

The change from baseline in Weight-Bearing Pain will be assessed using a 100-mm visual analogue scale ranging from 0 mm, no pain, to 100 mm, worst imaginable pain. Higher scores indicate more severe pain.

at week 12 after the first administration

二次結果の測定

結果測定
メジャーの説明
時間枠
Change from Baseline in Weight-Bearing Pain Visual Analogue Scale Score (0-100 mm)
時間枠:at Weeks 2, 4, and 24 after the first administration

The change from baseline in Weight-Bearing Pain will be assessed using a 100-mm visual analogue scale ranging from 0 mm, no pain, to 100 mm, worst imaginable pain. Higher scores indicate more severe pain.

at Weeks 2, 4, and 24 after the first administration
Change from Baseline in Western Ontario and McMaster Universities Osteoarthritis Index Total and Subscale Scores
時間枠:at Weeks 2, 4, 12, and 24 after the first administration

The change from baseline in the Western Ontario and McMaster Universities Osteoarthritis Index will be assessed for the pain, stiffness, and physical function subscales, as well as the total score. Each item is rated from 0 to 4, where 0 indicates no symptoms and 4 indicates extreme symptoms. Subscale scores are calculated by summing item scores, and the total score is calculated as the sum of the subscale scores. Higher scores indicate worse symptoms and poorer function.

at Weeks 2, 4, 12, and 24 after the first administration
Change from Baseline in 36-Item Short Form Health Survey Domain Scores (SF-36)
時間枠:at Weeks 2, 4, 12, and 24 after the first administration

The change from baseline in the 36-Item Short Form Health Survey (SF-36) will be assessed using the eight domain scores: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, and mental health. Each domain score ranges from 0 to 100, where higher scores indicate better health status/quality of life.

at Weeks 2, 4, 12, and 24 after the first administration
Change from Baseline in Rest Pain Visual Analogue Scale Score (0-100 mm)
時間枠:at Weeks 2, 4, 12, and 24 after the first administration

The change from baseline in Rest Pain will be assessed using a 100-mm visual analogue scale ranging from 0 mm, no pain, to 100 mm, worst imaginable pain. Higher scores indicate worse pain.

at Weeks 2, 4, 12, and 24 after the first administration
Change from Baseline in Motion Pain Visual Analogue Scale Score (0-100 mm)
時間枠:at Weeks 2, 4, 12, and 24 after the first administration

The change from baseline in Motion Pain will be assessed using a 100-mm visual analogue scale ranging from 0 mm, no pain, to 100 mm, worst imaginable pain. Higher scores indicate more severe pain.

at Weeks 2, 4, 12, and 24 after the first administration
Change from Baseline in Night Pain Visual Analogue Scale Score (0-100 mm)
時間枠:at Weeks 2, 4, 12, and 24 after the first administration

The change from baseline in Night Pain will be assessed using a 100-mm visual analogue scale ranging from 0 mm, no pain, to 100 mm, worst imaginable pain. Higher scores indicate more severe pain.

at Weeks 2, 4, 12, and 24 after the first administration
Change from Week 24 (Re-administration) in Weight-Bearing Pain Visual Analogue Scale Score (0-100 mm)
時間枠:at Week 36 (12 weeks after re-administration)

The change from Week 24, defined as the time of re-administration, in Weight-Bearing Pain will be assessed using a 100-mm visual analogue scale ranging from 0 mm, no pain, to 100 mm, worst imaginable pain.Higher scores indicate worse pain.

at Week 36 (12 weeks after re-administration)
Change from Week 24 (Re-administration) in Rest Pain Visual Analogue Scale Score (0-100 mm)
時間枠:at Week 36 (12 weeks after re-administration)

The change from Week 24, defined as the time of re-administration, in Rest Pain will be assessed using a 100-mm visual analogue scale ranging from 0 mm, no pain, to 100 mm, worst imaginable pain.Higher scores indicate worse pain.

at Week 36 (12 weeks after re-administration)
Change from Week 24 (Re-administration) in Motion Pain Visual Analogue Scale Score (0-100 mm)
時間枠:at Week 36 (12 weeks after re-administration)

The change from Week 24, defined as the time of re-administration, in Motion Pain will be assessed using a 100-mm visual analogue scale ranging from 0 mm, no pain, to 100 mm, worst imaginable pain. Higher scores indicate more severe pain.

at Week 36 (12 weeks after re-administration)
Change from Week 24 (Re-administration) in Night Pain Visual Analogue Scale Score (0-100 mm)
時間枠:at Week 36 (12 weeks after re-administration)

The change from Week 24, defined as the time of re-administration, in Night Pain will be assessed using a 100-mm visual analogue scale ranging from 0 mm, no pain, to 100 mm, worst imaginable pain. Higher scores indicate more severe pain.

at Week 36 (12 weeks after re-administration)
Change from Week 24 (Re-administration) in Western Ontario and McMaster Universities Osteoarthritis Index Total and Subscale Scores
時間枠:at Week 36 (12 weeks after re-administration)

The change from Week 24, defined as the time of re-administration, in the Western Ontario and McMaster Universities Osteoarthritis Index will be assessed for the pain, stiffness, and physical function subscales, as well as the total score. Each item is rated from 0 to 4, where 0 indicates no symptoms and 4 indicates extreme symptoms. Subscale scores are calculated by summing item scores, and the total score is calculated as the sum of the subscale scores. Higher scores indicate worse symptoms and poorer function.

at Week 36 (12 weeks after re-administration)
Change from Week 24 (Re-administration) in 36-Item Short Form Health Survey Domain Scores (SF-36)
時間枠:at Week 36 (12 weeks after re-administration)

The change from Week 24, defined as the time of re-administration, in the 36-Item Short Form Health Survey (SF-36) will be assessed using the eight domain scores: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, and mental health. Each domain score ranges from 0 to 100. Higher scores indicate better health status/quality of life.

at Week 36 (12 weeks after re-administration)

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Yong In, Ph.D、The Catholic University of Korea

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年7月3日

一次修了 (推定)

2026年12月1日

研究の完了 (推定)

2027年6月1日

試験登録日

最初に提出

2025年11月19日

QC基準を満たした最初の提出物

2025年11月24日

最初の投稿 (実際)

2025年12月5日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月5日

QC基準を満たした最後の更新が送信されました

2026年9月30日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • DLTS_05

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

未定

IPD プランの説明

Undecided. The plan for sharing individual participant data has not yet been determined.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する